ରୋପେଗିନଟରଫେରନ ଆଲଫା-୨ ବି

ରୋପେଗିନଟରଫେରନ ଆଲଫା-୨ ବି
Clinical data
Trade names	Besremi
Synonyms	AOP2014, ropeginterferon alfa-2b-njft
AHFS/Drugs.com	monograph
data	EU EMA: yes; US DailyMed: Ropeginterferon_alfa;
Pregnancy; category	Contraindicated;
Routes of; administration	Subcutaneous
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;

ରୋପେଗିନଟରଫେରନ ଆଲଫା-୨ ବି, (ଇଂରାଜୀ ଭାଷାରେ Ropeginterferon alfa-2b), ବେସ୍ରେମି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପଲିସିଥେମିଆ ଭେରା ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୧] ସାଧାରଣ ପ୍ଲୀହା ଥିବା ଲୋକଙ୍କଠାରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, କମ୍ ପ୍ଲାଟେଲେଟ୍, ମାଂସପେଶୀ ଓ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ଥକ୍କାଣ ଫ୍ଲୁ ପରି ଲକ୍ଷଣ ଏବଂ ଯକୃତ ପ୍ରଦାହ ହୋଇପାରେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା, ସଂକ୍ରମଣ, ଅଗ୍ନାଶୟ ପ୍ରଦାହ, ଆଖି ସମସ୍ୟା ଏବଂ ବୃକ୍‌କ ସମସ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୨] ଯକୃତ ଜନିତ ସମସ୍ୟା କିମ୍ବା ଭୟଙ୍କର ଅବସାଦ ଥିବା ଲୋକଙ୍କଠାରେ ଏହା ବ୍ୟବହାର କରାଯିବା ଉଚିତ୍ ନୁହେଁ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ଏହା ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୨] ଏହା ଏକ ପ୍ରକାର ଇଣ୍ଟରଫେରନ ଅଟେ ।^[୪]

୨୦୧୯ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୨୦୨୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ରୋପେଗିନଟରଫେରନ୍ ଆଲଫା-୨ ବି ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ୨୫୦ ମାଗ୍ରା ପାଇଁ ମୂଲ୍ୟ ୧୮୦୦ ଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ୨୦୨୨ ସୁଦ୍ଧା ପ୍ରାୟ ୩୬୦୦ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Besremi EPAR". European Medicines Agency (EMA). Archived from the original on 11 July 2022. Retrieved 14 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Besremi- ropeginterferon alfa-2b injection". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
↑ "FDA Approves Treatment for Rare Blood Disease". U.S. Food and Drug Administration (FDA) (Press release). 12 November 2021. Archived from the original on 11 July 2022. Retrieved 12 November 2021. This article incorporates text from this source, which is in the public domain.
↑ Wagner SM, Melchardt T, Greil R (March 2020). "Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera". Drugs of Today. Barcelona, Spain. 56 (3): 195–202. doi:10.1358/dot.2020.56.3.3107706. PMID 32282866.
↑ "Ropeginterferon alfa-2b". SPS - Specialist Pharmacy Service. 15 December 2015. Archived from the original on 24 October 2022. Retrieved 24 October 2022.
↑ "Besremi". goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[EPAR2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Besremi EPAR". European Medicines Agency (EMA). Archived from the original on 11 July 2022. Retrieved 14 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Besremi- ropeginterferon alfa-2b injection". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.

[FDA_PR_20211112-3] "FDA Approves Treatment for Rare Blood Disease". U.S. Food and Drug Administration (FDA) (Press release). 12 November 2021. Archived from the original on 11 July 2022. Retrieved 12 November 2021. This article incorporates text from this source, which is in the public domain.

[Wag2020-4] Wagner SM, Melchardt T, Greil R (March 2020). "Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera". Drugs of Today. Barcelona, Spain. 56 (3): 195–202. doi:10.1358/dot.2020.56.3.3107706. PMID 32282866.

[SPS2022-5] "Ropeginterferon alfa-2b". SPS - Specialist Pharmacy Service. 15 December 2015. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[6] "Besremi". goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]